Compare ALEMBIC with Fulford India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC vs FULFORD INDIA - Comparison Results

ALEMBIC     Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC FULFORD INDIA ALEMBIC/
FULFORD INDIA
 
P/E (TTM) x 60.8 398.8 15.2% View Chart
P/BV x 5.2 6.2 84.3% View Chart
Dividend Yield % 0.2 0.1 230.0%  

Financials

 ALEMBIC   FULFORD INDIA
EQUITY SHARE DATA
    ALEMBIC
Mar-18
FULFORD INDIA
Mar-14
ALEMBIC/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs72942 7.6%   
Low Rs34450 7.5%   
Sales per share (Unadj.) Rs4.7691.4 0.7%  
Earnings per share (Unadj.) Rs6.111.5 53.3%  
Cash flow per share (Unadj.) Rs6.215.4 40.7%  
Dividends per share (Unadj.) Rs0.202.00 10.0%  
Dividend yield (eoy) %0.40.3 131.4%  
Book value per share (Unadj.) Rs40.7380.0 10.7%  
Shares outstanding (eoy) m267.033.90 6,846.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.31.0 1,119.0%   
Avg P/E ratio x8.760.7 14.3%  
P/CF ratio (eoy) x8.545.3 18.7%  
Price / Book Value ratio x1.31.8 71.1%  
Dividend payout %3.317.4 18.8%   
Avg Mkt Cap Rs m14,1392,714 520.9%   
No. of employees `000NA0.4 0.0%   
Total wages/salary Rs m207505 41.1%   
Avg. sales/employee Rs ThNM6,073.0-  
Avg. wages/employee Rs ThNM1,137.4-  
Avg. net profit/employee Rs ThNM100.7-  
INCOME DATA
Net Sales Rs m1,2552,696 46.6%  
Other income Rs m370125 295.2%   
Total revenues Rs m1,6252,822 57.6%   
Gross profit Rs m111-46 -239.4%  
Depreciation Rs m3815 248.7%   
Interest Rs m210 17.9%   
Profit before tax Rs m44254 813.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2410 249.5%   
Profit after tax Rs m1,63045 3,646.2%  
Gross profit margin %8.9-1.7 -514.4%  
Effective tax rate %5.417.7 30.7%   
Net profit margin %129.81.7 7,832.7%  
BALANCE SHEET DATA
Current assets Rs m1,8671,738 107.4%   
Current liabilities Rs m591545 108.5%   
Net working cap to sales %101.644.3 229.6%  
Current ratio x3.23.2 99.0%  
Inventory Days Days9448 194.5%  
Debtors Days Days744 1,708.4%  
Net fixed assets Rs m1,79112 15,049.6%   
Share capital Rs m53439 1,369.5%   
"Free" reserves Rs m10,3241,443 715.4%   
Net worth Rs m10,8581,482 732.6%   
Long term debt Rs m410-   
Total assets Rs m11,5912,077 558.1%  
Interest coverage x260.96.7 3,884.6%   
Debt to equity ratio x00-  
Sales to assets ratio x0.11.3 8.3%   
Return on assets %14.12.6 539.4%  
Return on equity %15.03.0 497.7%  
Return on capital %15.24.3 352.8%  
Exports to sales %1.50-   
Imports to sales %21.024.5 85.8%   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m263659 39.9%   
Fx inflow Rs m1917 112.8%   
Fx outflow Rs m264673 39.2%   
Net fx Rs m-244-656 37.3%   
CASH FLOW
From Operations Rs m23690 262.0%  
From Investments Rs m-224105 -214.1%  
From Financial Activity Rs m-27-14 188.7%  
Net Cashflow Rs m-15181 -8.2%  

Share Holding

Indian Promoters % 64.0 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 0.2 3.8 5.3%  
FIIs % 9.7 0.1 9,700.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 21.2 123.1%  
Shareholders   54,701 4,783 1,143.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC With:   ALKEM LABORATORIES  FRESENIUS KABI ONCO.  GLENMARK PHARMA  TORRENT PHARMA  STRIDES PHARMA SCIENCE  

Compare ALEMBIC With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher, Coal India and UPL Among Top Gainers(Closing)

Indian share markets continued their positive trend during closing hours today and ended their day on a firm note.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (1QFY21); Net Profit Up 3.5% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY19); Net Profit Down 14.6% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY19); Net Profit Down 14.6% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

More Views on News

Most Popular

Intraday Trading for a Living(Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

Penny Stock Master Series: The Quest for 10X Profits in 10 Years(Profit Hunter)

Feb 12, 2021

This is first of the three part master series. In these editorials, I'll show you how to earn 10X returns from a penny stock portfolio over 10 years.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021(Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla(Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC SHARE PRICE


Feb 25, 2021 (Close)

TRACK ALEMBIC

  • Track your investment in ALEMBIC with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC - DISHMAN PHARMA COMPARISON

COMPARE ALEMBIC WITH

MARKET STATS